An initial open-label study of increasing doses of safinamide in PD showed added clinical benefits even when MAO-B inhibition was already achieved, but it remains debatable whether these functions are clinically relevant (Marzo et al. 2004; Stocchi et al. 2006). The gene discussed is MAOB; the disease is Parkinson disease.